Guide
21 CFR 106: Infant Formula cGMP After Abbott Sturgis
21 CFR 106 is the FDA infant-formula cGMP rule — distinct from 21 CFR 117 preventive controls and substantially stricter. It governs cGMP, quality control procedures, quality factors, notification requirements, records and audits for any infant formula sold in the US. Paired with 21 CFR 107 (the nutrient specification and labelling rule), it defines what an infant formula manufacturer must do before, during and after production. The Abbott Sturgis recall (February 2022) and the US infant-formula shortage exposed how brittle compliance can be even at the largest manufacturers, and FDA's 2024 enforcement intensity reflects that. This guide is the operating manual for a 21 CFR 106/107 programme that holds up under FDA's post-2022 scrutiny.
Start free trial Free trial, no credit card, onboard in days, not months.
21 CFR 106 vs 21 CFR 117 — why infant formula is its own rule
FDA's preventive controls rule (21 CFR 117) governs most human food. Infant formula sits outside it because Congress passed the Infant Formula Act (1980, amended 1986) which directs FDA to set a separate, stricter set of requirements — 21 CFR 106 (cGMP, QC, audits, notifications) and 21 CFR 107 (nutrient specifications and labelling). 106 requires periodic audits of the cGMP system; 117 requires only the underlying programme. 106 requires that nutrient testing on every batch confirm the 107 specifications. The two rules together are the strictest cGMP framework in the FDA food world.
Quality factors and 21 CFR 107.100 nutrient specifications
21 CFR 107.100 specifies the minimum and (for some) maximum levels of 29 nutrients in infant formula — protein, fat, linoleic acid, vitamins, minerals, choline, inositol — at the lowest level expected at the end of shelf life. The manufacturer tests every batch to confirm specification before release and retains samples for shelf-life confirmation. Quality factors under 106.96 require that the formula support normal physical growth, with the evidence either from a clinical growth study or from substantial equivalence to a previously approved formula. Changes to the formula trigger a new submission to FDA at least 90 days before marketing.
Notifications — 90-day pre-market, recall and adverse-event
Three distinct notifications under 21 CFR 106: (1) the new infant formula notification at least 90 days before marketing a new formula or a major manufacturing-change formula, with full chemistry, microbiology, packaging, label, quality-factor evidence and stability data; (2) recall notification under 106.121 when adulterated or misbranded product enters the market — within 24 hours of the decision; (3) MedWatch adverse-event reporting on any serious adverse event linked to the product. Each notification has a defined content set and a defined timeline.
Audits, recordkeeping and the FDA inspection
21 CFR 106 requires periodic audits of the cGMP system at a defined frequency, conducted by qualified individuals (typically a combination of internal and third-party). Records under 106.100 are retained for at least one year after the expiration date of the formula and produced on FDA demand. FDA's post-Sturgis inspection model is more aggressive — environmental sampling on Zones 1–4, batch records pulled at random, audit reports reviewed, recall protocols stress-tested. A weak audit programme is the fastest path to a 483 with significant observations.
Microbiological controls — Cronobacter, Salmonella and the EMP
21 CFR 106.55 and 106.61 require microbiological testing of finished product (Cronobacter sakazakii and Salmonella spp. as negative-in-X tests with statistically valid sampling). The EMP is required programmatically under 106.6 and was strengthened operationally by the 2024 FDA draft Cronobacter guidance. Microbiological failure on the finished-product test or a Zone 1 EMP positive on a food-contact surface is effectively recall-trigger. The microbiological programme is the visible top of an iceberg whose mass is the cGMP, sanitation, hygienic zoning and supplier control underneath.
A 120-day 21 CFR 106/107 readiness path
Days 1–20: 106/107 gap assessment — cGMP, QC, nutrient spec, quality factor, notifications, audit programme, recordkeeping. Days 21–45: nutrient-testing programme refresh — per-batch testing for all 29 nutrients in 107.100, shelf-life confirmation. Days 46–70: notification packets — 90-day pre-market template, recall protocol, MedWatch. Days 71–95: audit programme — internal audit schedule, third-party audit contracts, audit-report retention. Days 96–115: micro programme integration with the 2024 Cronobacter guidance. Days 116–120: mock FDA inspection with a recall-trace test.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Industries this hits hardest
Frequently asked
Does 21 CFR 106 replace 21 CFR 117 for infant formula?
Yes — infant formula is governed by 21 CFR 106 and 107 instead of 117. Some elements of 117's preventive controls philosophy are implicit in 106 (HACCP-style hazard analysis under 106.55 and 106.61), but the rule structure, the audit requirement, and the per-batch nutrient testing make 106 substantially stricter than 117.
Do I need FDA approval before launching a new infant formula?
Not approval — notification. Submit a new-formula notification at least 90 days before marketing. FDA reviews the notification and may object, ask for more data, or take no action. If FDA does not object within the 90-day window, the formula can be marketed. A major manufacturing change to an existing formula also requires a 90-day notification.
What counts as a 'major change' triggering notification?
21 CFR 106.30 defines major changes as those that affect a nutrient level, the formula composition, the manufacturing process in a way that may affect nutritional or safety characteristics, or the source of an essential nutrient. A change to a non-essential ingredient with no nutrient or safety impact is not a major change. Most multinationals run a change-control board with FDA-affairs review on every formula change.
How does the 2024 Cronobacter guidance interact with 21 CFR 106?
The guidance operationalises the microbiological-control expectations already implicit in 106.6, 106.55 and 106.61. The cGMP rule requires Cronobacter and Salmonella control; the 2024 guidance specifies how to do it (EMP density, hygienic zoning, finished-product testing). They're complementary — 106 is the regulation, the guidance is the operational standard FDA inspects against.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
- Food Processing cGMP Readiness: The V5 Hub
- Acrylamide Mitigation Readiness: EU 2017/2158 Benchmark Levels
- BRCGS Food Safety Issue 9 Readiness Guide
- Cronobacter & Powdered Infant Formula Readiness Guide
- Food Allergen Control & FALCPA Readiness Guide
- Food Fraud (VACCP) & Food Defense (TACCP) Readiness Guide
- Foreign Material Control & Metal Detection Readiness Guide
- FSMA 204 Food Traceability Readiness Guide (2026 Deadline)
Spot something off? .